Eloxx Pharmaceuticals Israeli Company

Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer.